TY - JOUR
TI - Cabozantinib and Vandetanib in medullary thyroid carcinoma: mitochondrial function and its potential as a therapeutic target towards novel strategies to design anti-CSCs drugs
AU - Tampaki, E.C.
AU - Tampakis, A.
AU - Droeser, R.
AU - Patsouris, E.
AU - Kouraklis, G.
JO - Cancer Biology and Therapy
PY - 2018
VL - 19
TODO - 10
SP - 847-849
PB - Taylor and Francis Inc.
SN - 1538-4047, 1555-8576
TODO - 10.1080/15384047.2018.1433495
TODO - cabozantinib;  placebo;  vandetanib;  anilide;  cabozantinib;  N-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine;  piperidine derivative;  pyridine derivative;  quinazoline derivative, apoptosis;  artery thrombosis;  bleeding;  bleeding disorder;  cancer patient;  cancer stem cell;  cardiovascular disease;  diarrhea;  digestive system fistula;  digestive system perforation;  drug approval;  epithelial mesenchymal transition;  European Medicines Agency;  fatigue;  follow up;  gastrointestinal disease;  hand foot syndrome;  human;  hypertension;  interstitial lung disease;  jaw osteonecrosis;  kidney failure;  Letter;  mental disease;  metabolic disorder;  mouth pain;  neurologic disease;  overall survival;  oxidative phosphorylation;  pneumonia;  posterior reversible encephalopathy syndrome;  progression free survival;  QT prolongation;  quality of life;  rash;  side effect;  skin disease;  stomatitis;  sudden death;  thyroid medullary carcinoma;  torsade des pointes;  vein thrombosis;  visual disorder;  wound healing;  mitochondrion;  thyroid tumor, Anilides;  Humans;  Mitochondria;  Piperidines;  Pyridines;  Quinazolines;  Thyroid Neoplasms
TODO - null
ER -